PrecisionLife Co-founder and Chief Business & Investment Officer, Rowan Gardner is speaking at Bio€quity Europe, the premier gathering of corporate investment communities for the European life sciences, which will take place 12-14 May 2024 in San Sebastián, Spain.
At Bio€quity Europe, Rowan will speak in R&D showcase #5, sharing her expertise in a special panel session.
14 May, 1:30 PM - 2:30 PM at the Kursaal Elkargunea Center
Europe's integrated healthcare systems and investments in innovative biobanks have created some of the richest biomedical data repositories in the world. The rapid acceleration of AI now promises to turn reams of data into actionable insights. This session will discuss how innovators like PrecisionLife are reducing AI to practice for target discovery and trial design using Europe's data hubs, and whether signal-finding this way can stand out against a sea of noise in this rapidly moving field.
PrecisionLife is a pioneering precision medicine company expanding the field beyond oncology and rare disease with its focus on complex chronic diseases, including CNS, autoimmune, cardiovascular, respiratory, and metabolic diseases that account for over 80% of healthcare spending.
We are unique in our ability to link mechanism of disease to specific patient subtypes that are likely to benefit from a drug targeting their specific mechanism. With this insight, we de-risk every stage of biopharma innovation, from target selection through to product launch and develop patient stratification biomarkers to enable patients likely to respond to be selected for clinical studies, be more accurately diagnosed and matched to the most effective personalized treatment.